Trade payables and short-term contract liabilities |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trade payables and short-term contract liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trade payables and short-term contract liabilities | Note 17. Trade payables and short-term contract liabilities
No calculations have been made to discount trade payables to present value as payment is due within one year at the end of the reporting period. Trade payables included €16.2 million, €20.7 million, and €12.9 million of accrued expenses as of December 31, 2025, 2024 and 2023, respectively. 17.1Trade payables Trade payables break down as follows:
As of December 31, 2025, trade payables were composed of accrued liabilities for €16.2 million of which €14.5 million related to scientific projects. As of December 31, 2025, trade payables decreased by €6.8 million compared to December 31, 2024. The variation in trade payables were mainly related to the research and development expenses in connection with the NATiV3 Phase III trial evaluating lanifibranor in MASH. |